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Pharmaceutical Strategy and the Evolving Role of Merger and Acquisition
Abstract
It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the
most adaptable to change.
Introduction
The sections in this chapter deal with a common set of topics: horizontal consolidation, merger and
acquisition (M&A), advantages of size, economies of scale and scope, diversification, and industry
concentration. These topics all interrelate around the fundamental issue in industrial organization: how best to
organize firms and markets in order to achieve optimal economic performance?
Consolidation has been rampant in most sectors of the healthcare industry since the 1980s and 1990s. Indeed,
the industry was the second most active in terms of M&A activity (behind finance) between 2008 and 2009.
In the pharmaceutical sector, the prior decades had been a time of growth and consolidation, as companies
leveraged both size and scale in bringing drugs to market. The current landscape, however, is one of new
challenges requiring new approaches to their solution. Companies are faced with internal pressures of
declining pipeline productivity and compressed timelines, external pressures of patent expiry and pricing, and
the uncertain implications of healthcare reform. Accompanying this evolution of challenges has been an
evolution in the strategic approaches taken by pharmaceutical companies to best position themselves for
success in the upcoming years.
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